U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07112222) titled 'A Study of LM-350 in Subjects With Advanced Solid Tumours' on July 16.
Brief Summary: For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350.
For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Malignant Tumors
Intervention:
DRUG: LM-350 for injection
Q3W,...